In yesterday’s Wall Street session, Royalty Pharma plc (NASDAQ:RPRX) shares traded at $25.67, down -0.96% from the previous session.
RPRX stock price is now -6.00% away from the 50-day moving average and -8.70% away from the 200-day moving average. The market capitalization of the company currently stands at $11.61B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $28, UBS recently Downgraded its rating from Buy to Neutral for Royalty Pharma plc (NASDAQ: RPRX). , while ‘Scotiabank’ rates the stock as ‘Sector Outperform’
In other news, RIGGS RORY B, Director sold 35,702 shares of the company’s stock on Jan 04 ’24. The stock was sold for $983,504 at an average price of $27.55. Upon completion of the transaction, the Director now directly owns 20,099 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 03 ’24, Director RIGGS RORY B sold 199,098 shares of the business’s stock. A total of $5,532,276 was realized by selling the stock at an average price of $27.79. This leaves the insider owning 55,801 shares of the company worth $1.43 million. A total of 15.04% of the company’s stock is owned by insiders.
During the past 12 months, Royalty Pharma plc has had a low of $25.83 and a high of $31.66. As of last week, the company has a debt-to-equity ratio of 0.94, a current ratio of 12.52, and a quick ratio of 12.52. According to the stock market information, the enterprise value for the company is $20208023552, which is based on a 14.41 price-to-earnings ratio, a 4.50 price-to-earnings-growth ratio, and a beta of 0.46. The fifty day moving average price for RPRX is $27.266 and a two-hundred day moving average price translates $28.1052 for the stock.
The latest earnings results from Royalty Pharma plc (NASDAQ: RPRX) was released for 2024-03-31. The net profit margin was 35.67% and return on equity was 12.84% for RPRX. The company reported revenue of $567.98 million for the quarter, compared to $683.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -16.96 percent.
